MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study

S. Isaacson, R. Pahwa, S. Thakkar, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Boca Raton, FL, USA)

Meeting: 2019 International Congress

Abstract Number: 113

Keywords: Deep brain stimulation (DBS), Levodopa(L-dopa), Parkinsonism

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: To evaluate the effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease who had previously undergone deep brain stimulation (DBS).

Background: Advanced therapies (such as DBS, CLES) may be considered when oral therapies cannot achieve adequate control of motor complications. Patients previously treated with DBS may still require dopaminergic therapy, and motor fluctuations may progress over time.(1) CLES has been shown to be effective as levodopa monotherapy, eliminating the need for other adjunctive dopaminergic medications.(2) The use of CLES in patients previously treated with DBS has been reported to be effective.(1,3-5)

Method: A sub-group of patients (n=13) from the PROviDE study who self-reported having DBS prior to initiation of CLES therapy were included in this analysis. PROviDE is a US-based real-world evidence study in patients initiating CLES.(6) Effectiveness was measured based on a standardized patient-reported outcomes for PD-related symptoms were collected via telephone-call or web-survey at baseline and regular intervals. In this interim analysis, effectiveness was measured as change from baseline at 3 months after initiating CLES therapy.

Results: The baseline demographic characteristics are presented [Table 1]. Patients with prior DBS tended to have longer disease duration (Mean±SD: 17.07±6.76 years) compared to the patient population of PROviDE study. About 85% of the patients required some assistance with walking. Compared to baseline, patients reported to have a significant reduction in off-time (Mean±SD: -2.08±2.81 hours/day; p<0.05) at 3-months. The patients also had a significant numerical improvement in the effectiveness domain of treatment satisfaction (Mean±SD: -14.23±16.21; p<0.05). Patients showed improvement (not significant) in other domains like dyskinesia, quality of life, sleep, fatigue, freezing of gait and overall treatment satisfaction (p>0.05) [Table 2].

Conclusion: Results from this sub-group analysis suggest that CLES may be a viable option for improving PD-symptoms in patients previously treated with DBS. Small sample sizes may challenge statistical comparisons. Additional research is needed to further understand patient characteristics and treatment modalities of using CLES in patients previously treated with DBS.

Table 1

Table 2

References: 1. El Kouzi, A. et al., 2018. Levodopa-Carbidopa Intestinal Gel (LCIG) in Deep Brain Stimulation (DBS) Parkinson’s Patients.(P6. 027). Neurology : Clinical practice., 90(15 Supplement), p.P6. 2. Buhmann, C. et al., 2017. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. Journal of Neural Transmission, 124(8), pp.1005–1013. 3. Kumar, N. et al., 2018. Levodopa‐carbidopa intestinal gel therapy after deep brain stimulation. Movement Disorders, 33(2), pp.334–335. 4. Klostermann, F., Jugel, C. & Marzinzik, F., 2011. Jejunal levodopa infusion in long‐term DBS patients with Parkinson’s disease. Movement Disorders, 26(12), pp.2298–2299. 5. Regidor, I.C. et al., 2017. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation–Refractory Symptoms in Advanced Parkinson Disease. Clinical Neuropharmacology, 40(3), pp.103–107. 6. Pahwa, R., 2018. Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics. Movement disorders, 33, p.S93.

To cite this abstract in AMA style:

S. Isaacson, R. Pahwa, S. Thakkar, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred. Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/efficacy-of-carbidopa-levodopa-enteral-suspension-cles-in-advanced-parkinsons-disease-patients-previously-treated-with-deep-brain-stimulation-dbs-a-subgroup-analysis-from-provid/. Accessed May 14, 2025.
  • Tweet
  • Email
  • Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-of-carbidopa-levodopa-enteral-suspension-cles-in-advanced-parkinsons-disease-patients-previously-treated-with-deep-brain-stimulation-dbs-a-subgroup-analysis-from-provid/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley